- 英文名称
- 10,12-Tricosadiynoic acid
- 分子式
- C23H38O2
- 分子量
- 346.547
- 中文别名
- 10,12-二十三联炔酸; tricosa-10,12-diynoic acid; MFCD00041683; 10,12-TRICOSADIYNOIC ACID
- 用途
- - 生物活性
10,12-Tricosadiynoic acid 是一种高特异性，选择性，高亲和力且具有口服活性的酰基辅酶 A 氧化酶-1 (ACOX1) 抑制剂。10,12-Tricosadiynoic acid 可改善线粒体脂质和 ROS 代谢，可用于高脂饮食或肥胖引起的代谢性疾病的研究。
- 靶点
Acyl-CoA oxidase-1 (ACOX1).
- 体外研究
10,12-Tricosadiynoic acid-CoA rapidly inhibits ACOX1 activity in a time- and concentration-dependent manner. The activity of ACOX1 decreases by nearly 95% after 5 min of incubation with 10 eq of 10,12-Tricosadiynoic acid-CoA. ACOX1 activity is inhibited only if free 10,12-Tricosadiynoic Acid is activated as the CoA thioester, the substrate form. Inhibition of ACOX1 by 10,12-Tricosadiynoic acid-CoA is irreversible. And the kinetics parameters KI and kinact are calculated to be 680 nm and 3.18 min
−1
, respectively.
10,12-Tricosadiynoic acid is the precursor of 10,12-Tricosadiynoic acid-CoA and is transformed into 10,12-Tricosadiynoic acid-CoA by peroxisomal very long chain acyl-CoA synthetase (VLACS) after entering into cells, and it inhibits ACOX1 in vivo.
10,12-Tricosadiynoic acid (500 nM) inhibits acyl-CoA oxidase-1 (ACOX1) activity. 10,12-Tricosadiynoic acid treatment abrogates the protective effect by Sirt5 siRNA.
- 体内研究
10,12-Tricosadiynoic acid (100 μg/kg; oral gavage; daily; for 8 weeks; male Wistar rats) treatment increases hepatic mitochondrial fatty acid oxidation (FAO) via activation of the SIRT1-AMPK (adenosine 5′-monophosphate-activated protein kinase) pathway and proliferator activator receptor α and reduces hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreases hepatic lipid and ROS contents, reduces body weight gain, and decreases serum triglyceride and insulin levels.
10,12-Tricosadiynoic acid (0 mg/kg, 37.5 mg/kg, 75 mg/kg, and 150 mg/kg diet) treatment does not affect weight gain, but significantly decreases peroxisomal β-oxidation in the liver, and increased body fat accumulation in Nile tilapia. The fish with impaired peroxisomal β-oxidation exhibited higher contents of serum lipid and peroxidation products, and alanine aminotransferase activity, and significantly lowered hepatic activities of superoxide dismutase and catalase.
Animal Model:
Male Wistar rats (210-230 g) fed with high fat diet
Dosage:
100 μg/kg
Administration:
Oral gavage; daily; for 8 weeks
Result:
Reduced hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreased hepatic lipid and ROS contents, reduced body weight gain, and decreased serum triglyceride and insulin levels.
